Quick Answer
Neuphoria Therapeutics Inc. reported Cash and Equivalents of $14.21 million for fiscal year 2025.
Neuphoria Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $14.21M | +12.7% |
| 2024 | $12.61M | +4.2% |
| 2023 | $12.10M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $22.17M | +410.3% | +62.4% |
| September 30, 2025 | $13.65M | +68.9% | -3.9% |
| June 30, 2025 | $14.21M | +12.7% | -16.6% |
| March 31, 2025 | $17.04M | +102.3% | +292.3% |
| December 31, 2024 | $4.34M | -57.2% | -46.2% |
| September 30, 2024 | $8.08M | -0.6% | -35.9% |
| June 30, 2024 | $12.61M | — | +49.6% |
| March 31, 2024 | $8.43M | — | -17.0% |
- Neuphoria Therapeutics Inc. showed an increase of +12.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Neuphoria Therapeutics Inc.’s cash and equivalents has grown by 17.4% (from $12.10 million to $14.21 million).
- The most recent figure is from Neuphoria Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: